The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 28, 2005

Filed:

Feb. 22, 2001
Applicants:

Emmanuelle Vigne, L′Hay-les-Roses, FR;

Jean-francois Dedieu, Paris, FR;

Martine Latta, Charenton le Pont, FR;

Patrice Yeh, Gif sur Yvette, FR;

Michel Perricaudet, Ecrosnes, FR;

Inventors:

Emmanuelle Vigne, L′Hay-les-Roses, FR;

Jean-Francois Dedieu, Paris, FR;

Martine Latta, Charenton le Pont, FR;

Patrice Yeh, Gif sur Yvette, FR;

Michel Perricaudet, Ecrosnes, FR;

Assignee:

Aventis Pharma S.A., Antony Cedex, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K048/00 ; C12N015/63 ;
U.S. Cl.
CPC ...
Abstract

Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g., for gene therapy of cancers or cardiovascular conditions.


Find Patent Forward Citations

Loading…